Noteworthy Monday Option Activity: MDB, XENE, SNOW

Xenon Pharmaceuticals (XENE) saw 6,057 option contracts trade today (≈605,700 underlying shares), equal to ~79.2% of its one‑month average daily volume; notable activity included 2,000 contracts in the $30 put expiring April 17, 2026 (≈200,000 shares). Snowflake (SNOW) recorded 42,519 option contracts (≈4.25M underlying shares), about 76.1% of its one‑month average daily volume, with 2,265 contracts in the $250 call expiring December 12, 2025 (≈226,500 shares). The flows indicate concentrated derivatives positioning that may drive intraday liquidity and volatility in both names but do not convey fundamental company news.

Analysis

Market structure: The outsized option flow (XENE ~6,057 contracts incl. 2,000 Apr‑17‑2026 $30 puts; SNOW ~42,519 contracts incl. 2,265 Dec‑12‑2025 $250 calls) indicates concentrated directional exposure that can create short‑term order flow asymmetry. Market makers selling those options will delta‑hedge (buy SNOW stock on call sales, sell XENE on put buys), amplifying price moves into the next 1–10 trading days and increasing IV in those expiries by +20–50 bps if flows continue.

Risk assessment: Tail risks are asymmetric — XENE faces binary biotech/regulatory outcomes that can wipe out >50% in weeks; SNOW is exposed to macro/software spend cycles that could subtract 20–30% in a tech drawdown. Hidden: printed trades may be multi‑leg spreads (synthetic or short puts) rather than naked directional bets; verify block trade/clearing data before scaling. Key catalysts: XENE trial reads/FDA timelines before Apr‑2026 and SNOW revenue/guide updates or cloud spend prints into Dec‑2025.

Trade implications: For directional exposure favor defined‑risk option structures to capture flow‑driven gamma: buy SNOW Dec12‑2025 250/300 call debit spreads (limited cost, levered to upside) and buy XENE Apr‑2026 30/20 put debit spreads (protects downside). Size initial positions small (0.5–2% portfolio per trade), scale into confirmed delta‑hedging price action over 3–10 days, and trim ahead of the expiries or company catalysts.

Contrarian angles: Consensus reads as simple long SNOW / short XENE, but flows could be premium sellers or hedges — if XENE puts are mostly sold (short puts), downside is smaller and IV compression is likely, creating a short‑vol opportunity. Historical parallel: concentrated option activity ahead of catalysts often reverses once liquidity providers unwind hedges; be ready to fade initial move after IV declines 30–40% or after 5–10 trading days of mean reversion.

Key Decisions for Investors

• Establish a 1% portfolio allocation to SNOW via Dec‑12‑2025 250/300 call debit spreads (buy 250 / sell 300) to limit max loss; target a 50–100% midpoint return by Nov‑2025; cut position if SNOW closes below $200 on a 5‑day average or if IV rises >60% from entry.
• Establish a 0.75% portfolio allocation to XENE via Apr‑17‑2026 30/20 put debit spreads (buy 30 / sell 20) as a defined‑risk hedge/speculative downside play; target >100% payoff if XENE < $25 by expiry; exit/roll if XENE > $38 for 10 consecutive trading days or IV compresses by >40%.
• Implement a relative‑value pair: long SNOW equity (0.5%) and short MDB equity (0.5%) to express cloud vendor dispersion; hold 3–6 months, trim if the pair mean‑reverts by 15% or if SNOW reports disappointing ARR/guide.
• If post‑trade IV for XENE spikes and you verify put sellers (short puts) via tape/OTC checks, initiate a small (0.25%) short‑vol trade: sell monthly iron condors around current strikes 30±10, max risk defined, and close after IV compression of 30–40% or 2–4 weeks.